Published in Crit Care Med on October 01, 2003
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol (2005) 4.83
Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis (2007) 3.73
Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care (2006) 2.07
Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens. J Clin Microbiol (2006) 1.87
Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care (2011) 1.10
Nosocomial and ventilator-associated pneumonia in a community hospital intensive care unit: a retrospective review and analysis. BMC Res Notes (2014) 1.01
Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care (2005) 0.92
Ventilator-associated pneumonia. Australas Med J (2014) 0.86
Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Crit Care Med (2003) 0.84
Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms. Transl Med UniSa (2012) 0.80
Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii. Antimicrob Agents Chemother (2015) 0.78
Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis. BMC Infect Dis (2016) 0.78
Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia. Support Care Cancer (2015) 0.76
Biofilm Formation and Motility Depend on the Nature of the Acinetobacter baumannii Clinical Isolates. Front Public Health (2016) 0.76
World-wide variation in incidence of Acinetobacter associated ventilator associated pneumonia: a meta-regression. BMC Infect Dis (2016) 0.75
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis (2003) 3.93
Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med (2002) 3.63
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med (2004) 3.49
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care (2009) 3.48
Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. Thorax (2013) 3.05
Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med (2007) 2.94
Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients*. Crit Care Med (2014) 2.86
Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med (2007) 2.44
Patients with New York Heart Association class III heart failure may benefit with high flow nasal cannula supportive therapy: high flow nasal cannula in heart failure. J Crit Care (2013) 2.43
Oral care practices in intensive care units: a survey of 59 European ICUs. Intensive Care Med (2007) 2.43
Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest (2003) 2.31
Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med (2004) 2.30
Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med (2010) 2.29
Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med (2007) 2.22
A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med (2007) 2.08
A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med (2012) 2.06
Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med (2003) 1.98
Acinetobacter baumannii: a threat for the ICU? Intensive Care Med (2003) 1.93
Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis (2003) 1.90
Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med (2009) 1.89
Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med (2005) 1.88
A randomized trial of dental brushing for preventing ventilator-associated pneumonia. Chest (2009) 1.87
Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis (2004) 1.85
De-escalation therapy in ventilator-associated pneumonia. Crit Care Med (2004) 1.85
New issues and controversies in the prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med (2010) 1.84
Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents (2011) 1.80
Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med (2014) 1.77
Incidence, etiology, and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation. Chest (2003) 1.71
Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest (2003) 1.68
Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia. Crit Care Med (2007) 1.66
Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med (2006) 1.65
Host adaptive immunity deficiency in severe pandemic influenza. Crit Care (2010) 1.64
Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia. Crit Care Med (2003) 1.61
Severe 2009 A/H1N1v influenza in pregnant women in Spain. Crit Care Med (2011) 1.61
Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med (2005) 1.60
Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med (2004) 1.58
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med (2013) 1.50
Centers for Disease Control and Prevention guidelines for preventing central venous catheter-related infection: results of a knowledge test among 3405 European intensive care nurses. Crit Care Med (2009) 1.48
Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med (2014) 1.48
Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. Crit Care Med (2013) 1.48
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med (2012) 1.47
Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J (2013) 1.45
Effect of high-flow nasal cannula and body position on end-expiratory lung volume: a cohort study using electrical impedance tomography. Respir Care (2013) 1.42
Severity of illness assessment for managing community-acquired pneumonia. Intensive Care Med (2007) 1.42
Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med (2009) 1.40
Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest (2009) 1.40
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet (2011) 1.39
Pneumonia in the intensive care unit. Crit Care Med (2003) 1.36
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ (2010) 1.33
Hybrid pathogenicity island PAGI-5 contributes to the highly virulent phenotype of a Pseudomonas aeruginosa isolate in mammals. J Bacteriol (2008) 1.33
Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol (2008) 1.25
C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med (2008) 1.25
Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS One (2012) 1.23
Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med (2009) 1.21
Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med (2004) 1.19
C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intensive Care Med (2004) 1.17
Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care (2008) 1.17
Ventilator-associated pneumonia: issues related to the artificial airway. Respir Care (2005) 1.13
Impact of obesity in patients infected with 2009 influenza A(H1N1). Chest (2010) 1.13
Genomic islands of Pseudomonas aeruginosa. FEMS Microbiol Lett (2008) 1.12
Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care (2011) 1.10
Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol (2013) 1.10
The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest (2008) 1.09
Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med (2013) 1.09
Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents (2010) 1.07
Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother (2003) 1.06
Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest (2008) 1.04
Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother (2006) 1.03
Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest (2008) 1.03
Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother (2011) 1.02
Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother (2010) 1.02
Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opin Pulm Med (2012) 1.01
Management of ventilator-associated pneumonia caused by multiresistant bacteria. Curr Opin Crit Care (2007) 1.00
Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis (2013) 0.99
Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med (2008) 0.98
Why mortality is increased in health-care-associated pneumonia: lessons from pneumococcal bacteremic pneumonia. Chest (2009) 0.98
Gram-negative bacterial pneumonia: aetiology and management. Curr Opin Pulm Med (2006) 0.98
Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest (2006) 0.97
The role of mannose-binding lectin in pneumococcal infection. Eur Respir J (2012) 0.96